Tibet Cheezheng Tibetan Medicine Co Ltd - Asset Resilience Ratio
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) has an Asset Resilience Ratio of 41.25% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Tibet Cheezheng Tibetan Medicine Co Ltd (002287) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Tibet Cheezheng Tibetan Medicine Co Ltd's Asset Resilience Ratio has changed over time. See 002287 book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Tibet Cheezheng Tibetan Medicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002287 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.74 Billion | 41.25% |
| Total Liquid Assets | CN¥2.74 Billion | 41.25% |
Asset Resilience Insights
- Very High Liquidity: Tibet Cheezheng Tibetan Medicine Co Ltd maintains exceptional liquid asset reserves at 41.25% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Tibet Cheezheng Tibetan Medicine Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tibet Cheezheng Tibetan Medicine Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Tibet Cheezheng Tibetan Medicine Co Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Tibet Cheezheng Tibetan Medicine Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 41.34% | CN¥2.81 Billion ≈ $410.80 Million |
CN¥6.79 Billion ≈ $993.65 Million |
+10.18pp |
| 2023-12-31 | 31.17% | CN¥1.96 Billion ≈ $287.26 Million |
CN¥6.30 Billion ≈ $921.67 Million |
+5.02pp |
| 2022-12-31 | 26.15% | CN¥1.54 Billion ≈ $225.25 Million |
CN¥5.89 Billion ≈ $861.40 Million |
+4.88pp |
| 2021-12-31 | 21.26% | CN¥1.18 Billion ≈ $173.25 Million |
CN¥5.57 Billion ≈ $814.74 Million |
+20.18pp |
| 2019-12-31 | 1.08% | CN¥32.28 Million ≈ $4.72 Million |
CN¥2.98 Billion ≈ $436.67 Million |
-17.94pp |
| 2018-12-31 | 19.02% | CN¥440.00 Million ≈ $64.39 Million |
CN¥2.31 Billion ≈ $338.43 Million |
+0.69pp |
| 2017-12-31 | 18.33% | CN¥421.00 Million ≈ $61.61 Million |
CN¥2.30 Billion ≈ $336.06 Million |
+8.70pp |
| 2016-12-31 | 9.64% | CN¥200.00 Million ≈ $29.27 Million |
CN¥2.08 Billion ≈ $303.74 Million |
-3.41pp |
| 2015-12-31 | 13.04% | CN¥270.00 Million ≈ $39.51 Million |
CN¥2.07 Billion ≈ $302.93 Million |
-5.76pp |
| 2014-12-31 | 18.81% | CN¥337.00 Million ≈ $49.31 Million |
CN¥1.79 Billion ≈ $262.21 Million |
-- |
About Tibet Cheezheng Tibetan Medicine Co Ltd
Tibet Cheezheng Tibetan Medicine Co., Ltd. engages in the research, development, production, and sale of Tibetan medicines in China and internationally. The company also provides plasters, topical and oral tibetan medicines, and ointments. Its products are used in areas of orthopedics, neurology, dermatology, granules, gynecology, pediatrics, respiratory, gastroenterology, cardiovascular, musculo… Read more